Meeting
2012 ASCO Annual Meeting
Tolerability and efficacy of a biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin regimen (TFOX) in previously advanced metastatic gastric and oesogastric junction (AGC) adenocarcinoma.
Authors
Simon Pernot
Hôpital Européen Georges Pompidou, Paris, France
Simon Pernot , Emmanuel Mitry , Emmanuelle Samalin , Laetitia Dahan , Hajer Turki , Thibault Mazard , Marc Ychou , Jean Francois Seitz , Philippe Rougier , Julien Taïeb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal, Gastric, or Small Bowel
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4087)
DOI
10.1200/jco.2012.30.15_suppl.4087
Abstract #
4087
Poster Bd #
46F
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma.
First Author: Vikas S. Ostwal
Poster
2023 ASCO Annual Meeting
Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas.
First Author: Kohei Shitara
Poster
2018 Gastrointestinal Cancers Symposium
Patterns of chemotherapy (CT) use in a U.S.-wide cohort of patients (pts) with metastatic gastric cancer (MGC).
First Author: Thomas Adam Abrams
Poster
2017 Gastrointestinal Cancers Symposium
A pilot study of apatinib reversing paclitaxel resistance in heavily pretreated advanced gastric cancer (AGC).
First Author: Rongbo Lin